Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: the phase 3 KEYNOTE-062 study
Tabernero, J van Cutsem, E Bang, Y Fuchs, C Wyrwicz, L Lee, K Kudaba, I Garrido, M Chung, C Salguero, CC
Tabernero, J
van Cutsem, E
Bang, Y
Fuchs, C
Wyrwicz, L
Lee, K
Kudaba, I
Garrido, M
Chung, C
Salguero, CC
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Tabernero J, Van Cutsem E, Bang Y-J, Fuchs CS, Wyrwicz L, Lee KW, et al. Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: the phase III KEYNOTE-062 study. Ann Oncol, 30(Supplement_4).